ClinicalTrials.gg
RecruitingNCT07848516Updated Nov 4, 2026

Change in Fat Fraction Quantification Before and After Treatment in Bone Metastases

An observational study in Neoplasm Metastasis / Bone and Bones, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Assiut University · Observational

Updated Nov 4, 2026Now RecruitingFirst site in Egypt+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
84
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neoplasm Metastasis by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Neoplasm Metastasis · Assiut University.

Started
2026
with 3 others
Observational
8 of 11
5 open now
Registered
9th of 11
by date

Among the 11 studies in Neoplasm Metastasis by Assiut University, this one is one of 4 that started in 2026, is one of 8 observational ones, and was the 9th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

7 of the 11 studies in Neoplasm Metastasis by Assiut University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neoplasm Metastasis by Assiut University, or all of them as a file.
02

Study summary

Bone metastases are a common and serious complication of cancer. Treatment response is currently judged mainly by delayed changes on CT scans or X-rays, a process that can take months and sometimes produces misleading results. The study investigates whether a specialized, radiation-free MRI technique called Dixon imaging can detect early signs of treatment response by measuring fat content within bone metastases before and after chemotherapy or radiotherapy. As tumor tissue within a bone lesion responds to treatment, the lesion is expected to be gradually replaced by fatty marrow, a change that can be quantified using the Dixon MRI method. Adult patients with a solid-tumor cancer and at least one lytic (bone-destroying) metastasis will undergo an MRI scan before starting treatment and a second MRI scan after completing chemotherapy or radiotherapy. Change in fat content within the lesion, and relative to normal marrow, will be measured and compared between patients receiving chemotherapy versus radiotherapy. The study does not involve additional radiation, contrast injection, or invasive procedures beyond standard MRI, and does not influence treatment decisions, which remain under the direction of the treating oncology team.

03

Conditions studied

  • Neoplasm Metastasis / Bone and Bones

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with solid-tumor malignancy with ≥1 lytic bone metastasis (≥1 cm)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Solid-tumor with ≥1 lytic bone (≥1 cm) confirmed on CT. (When a patient has more than one qualifying lytic lesion, the largest and/or most accessible lesion (whichever allows more reliable, artifact-free ROI placement) will be selected for analysis.)
  • Scheduled for chemotherapy or radiotherapy to the involved region.
  • Age ≥18, able to undergo MRI,
  • given.

Exclusion criteria

Exclusion Criteria:

  • Sclerotic/mixed lesions.
  • Prior focal treatment to the lesion.
  • Pathological fracture at the site.
  • Patients receiving concurrent bone-targeting therapy (bisphosphonates or denosumab) during the study period, as these independently alter marrow fat content.
  • MRI .
  • Inability to complete follow-up scan.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
84 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • Diagnostic testMRI Non-contrast

    Participants will undergo 1.5 Tesla MRI examinations including conventional T1/T2-weighted sequences and a T1-weighted Dixon sequence, performed at two time points: at baseline, within one week prior to initiation of chemotherapy or radiotherapy, and again after completion of the treatment course. Fat-only and water-only Dixon image sets will be generated, and regions of interest will be placed on the target lytic bone metastasis and on a reference region of normal-appearing marrow. Relative fat fraction (rFF) will be calculated within each region from the ratio of fat-signal intensity to combined fat-and-water signal intensity, and a normalized fat fraction ratio (FFR) will be derived as lesion rFF divided by reference-region rFF. Diffusion-weighted imaging and apparent diffusion coefficient values will be obtained where feasible as an exploratory measure. No contrast agent, radiotracer, or ionizing radiation is administered as part of the imaging procedure, and no additional invasive

06

What researchers measure

Primary outcomes

  1. Change in Fat Fraction Ratio of Lytic Bone Metastases

    Change in the normalized fat fraction ratio (FFR, lesion rFF divided by reference-region rFF), calculated as the difference between pre-treatment and post-treatment values for each participant.

    Time frame: Baseline and a follow-up at 4 to 12 weeks after completion of the chemotherapy or radiotherapy course

Secondary outcomes

  1. Comparison of Change in Fat Fraction Ratio Between Chemotherapy and Radiotherapy Subgroups

    Comparison of change in the normalized fat fraction ratio (FFR) between participants receiving chemotherapy versus radiotherapy

    Time frame: Baseline and a follow-up at 4 to 12 weeks after completion of the chemotherapy or radiotherapy course

  2. Inter-observer Agreement for Fat Fraction Ratio Measurements

    Agreement between two independent observers' fat fraction ratio (FFR) measurements in a subset of re-measured lesions

    Time frame: Baseline and a follow-up at 4 to 12 weeks after completion of the chemotherapy or radiotherapy course

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Park S, Do Huh J. Differentiation of bone metastases from benign red marrow depositions of the spine: the role of fat-suppressed T2-weighted imaging compared to fat fraction map. Eur Radiol. 2022 Oct;32(10):6730-6738. doi: 10.1007/s00330-022-08965-3. Epub 2022 Jul 7. PubMed 35798881 ↗
  • Takasu M, Kondo S, Akiyama Y, Takahashi Y, Maeda S, Baba Y, Kawase T, Ichinohe T, Awai K. Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS One. 2020 Feb 27;15(2):e0229607. doi: 10.1371/journal.pone.0229607. eCollection 2020. PubMed 32106239 ↗
  • Koutoulidis V, Terpos E, Papanikolaou N, Fontara S, Seimenis I, Gavriatopoulou M, Ntanasis-Stathopoulos I, Bourgioti C, Santinha J, Moreira JM, Kastritis E, Dimopoulos MA, Moulopoulos LA. Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. Radiology. 2022 Jul;304(1):137-144. doi: 10.1148/radiol.211388. Epub 2022 Apr 5. PubMed 35380497 ↗
  • Schmeel FC, Vomweg T, Traber F, Gerhards A, Enkirch SJ, Faron A, Sprinkart AM, Schmeel LC, Luetkens JA, Thomas D, Kukuk GM. Proton density fat fraction MRI of vertebral bone marrow: Accuracy, repeatability, and reproducibility among readers, field strengths, and imaging platforms. J Magn Reson Imaging. 2019 Dec;50(6):1762-1772. doi: 10.1002/jmri.26748. Epub 2019 Apr 13. PubMed 30980694 ↗
  • Castagnoli F, Donners R, Tunariu N, Messiou C, Koh DM. Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement. Br J Radiol. 2023 Dec;96(1152):20230240. doi: 10.1259/bjr.20230240. Epub 2023 Oct 31. PubMed 37750943 ↗
  • Azma YN, Boci N, Abramowicz K, Russo L, Orton MR, Tunariu N, Koh DM, Charles-Edwards G, Collins DJ, Winfield JM. Influence of imaging method on fat fraction estimation for assessing bone marrow in metastatic prostate cancer. Eur Radiol. 2025 Oct;35(10):6039-6051. doi: 10.1007/s00330-025-11564-7. Epub 2025 Apr 11. PubMed 40214737 ↗
  • Lecouvet FE, Taihi L, Kirchgesner T, Pasoglou V, Halut M, Tuba Sanal H, Gitto S, Martin-Noguerol T, Vasilevska-Nikodinovska V, Vanhoenacker F, Vilanova JC. ESR Essentials: bone marrow MRI in oncology-practice recommendations by the European Society of Musculoskeletal Radiology. Eur Radiol. 2026 Jul;36(7):5414-5428. doi: 10.1007/s00330-025-12307-4. Epub 2026 Feb 9. PubMed 41663831 ↗
  • Carmona R, Pritz J, Bydder M, Gulaya S, Zhu H, Williamson CW, Welch CS, Vaida F, Bydder G, Mell LK. Fat composition changes in bone marrow during chemotherapy and radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):155-63. doi: 10.1016/j.ijrobp.2014.05.041. Epub 2014 Jul 8. PubMed 25015207 ↗
  • Latifoltojar A, Hall-Craggs M, Bainbridge A, Rabin N, Popat R, Rismani A, D'Sa S, Dikaios N, Sokolska M, Antonelli M, Ourselin S, Yong K, Taylor SA, Halligan S, Punwani S. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. Eur Radiol. 2017 Dec;27(12):5325-5336. doi: 10.1007/s00330-017-4907-8. Epub 2017 Jun 27. PubMed 28656463 ↗
  • Park S, Huh JD. Bone metastases with post-treatment intralesional fatty content of the spine: imaging features from T1-weighted imaging with CT finding correlations. Acta Radiol. 2023 Jan;64(1):153-163. doi: 10.1177/02841851211058930. Epub 2021 Dec 1. PubMed 34851180 ↗
  • Qin C, Goldberg O, Kakar G, Wan S, Haroon A, Azam A, Adeleke S. MRI fat fraction imaging of nodal and bone metastases in prostate cancer. Eur Radiol. 2023 Aug;33(8):5851-5855. doi: 10.1007/s00330-023-09527-x. Epub 2023 Mar 16. PubMed 36928564 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2029, 27 months later.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 27 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 30, 2026
StartEst.
Nov 10, 2026was Oct 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Nov 1, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
1 site added — first site in Egypt
Show site
  • South Egypt Cancer Institute, Assiut University · Asyut, Egypt
Nov 4, 2026
Start date
Oct 1, 2026→Nov 10, 2026
Nov 4, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Egypt
    Show site
    • South Egypt Cancer Institute, Assiut University · Asyut, Egypt
    Start date Oct 1, 2026→Nov 10, 2026
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848516
Lead sponsor
Assiut University
Responsible party
Ibrahem Abdelnaser Ahmed Zohry (Radiology resident, Assiut University) — Principal investigator
First posted
Sep 30, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Ibrahem Abdelnaser Zohry, MBBCh
Contact
ibrahim.18313355@med.aun.edu.eg
+201555433075
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion